Research on the impact of the adjustment of National Reimbursement Drug List on drug use of rare disease in hospitals
- VernacularTitle:医保目录调整对医院罕见病用药的影响研究
- Author:
Hongbin YI
1
;
Fenghao SHI
2
;
Liping KUAI
3
;
Hua XING
1
Author Information
1. School of Business Administration，Shenyang Pharmaceutical University，Shenyang 110016，China
2. International Research Center for Medical Administration，Peking University，Beijing 100191，China
3. Science and Technology Development Center of Chinese Pharmaceutical Association，Beijing 100022，China
- Publication Type:Journal Article
- Keywords:
national reimbursement drug list;
rare disease;
interrupted time series analysis;
defined daily dose cost;
defined
- From:
China Pharmacy
2022;33(24):2952-2956
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To explore the impact of the adjustment of the national reimbursement drug list on rare disease drugs in hospitals， and to provide reference for improving the drug security of patients with rare diseases in China.METHODS The monthly procurement data of rare disease drugs from 789 medical institutions that continuously reported data from January 2016 to December 2018 were extracted from the Chinese Medicine Economic Information. The single-group interrupted time series model was used to compare drug varieties， procurement amount， average defined daily cost （DDDc） and defined daily doses （DDDs） of rare disease drugs before and after the adjustment of national reimbursement drug list. RESULTS In 2017， a total of 9 rare disease drugs were newly included in the national reimbursement drug list， including pirfenidone， carbidopa/levodopa， riluzole， ropinirole， droxidopa， ezetimibe， everolimus， coagulation factor Ⅸ human recombinant and coagulation factor Ⅶa human recombinant. After the adjustment of the national reimbursement drug list， the average DDDc of 9 rare disease drugs was significantly decreased， the upward trend of DDDs and the procurement amount was significantly increased （P＜0.001）. CONCLUSIONS The number of newly included rare disease drugs in national reimbursement drug list keeps increasing， the coverage of medical security keeps expanding， the price of rare disease drugs is significantly decreased， the economic burden of patients is further decreased， and the consumption of rare disease drugs is significantly increased， benefiting more patients with rare diseases； but at the same time， it also increases the procurement amount of rare disease drugs in hospitals. National medical security departments need to fully consider how to balance the affordability of medical insurance funds with the demand for rare disease drug coverage.
